SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.

Altre lingue Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

Azioni

600196

CNE000000X38

Prezzo di chiusura Shanghai S.E. Altri mercati azionari 00:00:00 18/04/2024			Variaz. 5gg	Var. 1 gen.
22,77 ^CNY	-0,04%		-0,74%	-9,03%

08/04	La Cina accetta le richieste di nuovi farmaci per la sindrome da sovraccarico di ferro di Fosun Pharma	MT
27/03	Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHSE:600196) annuncia un riacquisto di azioni per un valore di 200 milioni di CNY.	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

China Approves Fosun Unit's Phase 2 Clinical Trial for Cancer Combination Therapy	18/04
Fosun Pharma Unit’s New Drug Application for CMV, HSV Drug Accepted by Chinese Regulator	17/04
Revance to Present New DAXXIFY Data at the American Academy of Neurology 2024 Annual Meeting	15/04
China Accepts New Drug Applications for Fosun Pharma's Iron Overload Syndrome Drugs	08/04
Tranche Update on Shanghai Fosun Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on March 27, 2024.	03/04
Fosun Pharma's 2023 Attributable Profit Declines, Misses Estimates	27/03
Shanghai Fosun Pharmaceutical Co., Ltd. announces an Equity Buyback for CNY 200 million worth of its shares.	27/03
Shanghai Fosun Pharmaceutical Co., Ltd. Proposes Final Dividend for the Year Ended 31 December 2023	26/03
Shanghai Fosun Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	26/03
Shanghai Fosun Pharmaceutical Co., Ltd. authorizes a Buyback Plan.	26/03
Shanghai Fosun Pharma Unit's Oral Schizophrenia Drug Gets Marketing Registration	14/03
Fosun Pharma Unit Gets China OK for Phase I Trial for Solid Tumor Drug	08/03
Fosun Pharma Unit to Start First Phase of Trial of Cancer Drug Candidate	08/03
Fosun Pharma Chairman Proposes Buyback of Up to 200 Million Yuan	04/03
Fosun Pharma Subsidiaries Get Nod to Trial Leukemia Drugs	01/03
Registration Application of Hypokalemia Drug by Shanghai Fosun Pharmaceutical Unit Accepted by Chinese Regulator	20/02
Yuyuan Tourist Mart CFO Steps Down	05/02
Shanghai Fosun Unit Gets Clearance For China Phase II Trial of Amyloidosis Drug	25/01
Glycotest, Inc. announced that it has received $1 million in funding from EMV Capital Ltd, NetScientific plc, Shanghai Fosun Pharmaceutical Co., Ltd.	23/01
China Grants Clinical Trial Approval for Fosun Pharma Unit's Bronchiectasis Tablets	16/01

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

Azioni

600196

CNE000000X38

Altre lingue

Filtri